Ultimovacs ASA reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was NOK 22.75 million compared to NOK 34.11 million a year ago. Basic loss per share from continuing operations was NOK 0.7 compared to NOK 1 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.8 NOK | -4.99% | -6.25% | -93.65% |
Jun. 11 | Ultimovacs Asa Provides Update from Phase I Study in Malignant Melanoma | CI |
May. 07 | Transcript : Ultimovacs ASA, Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-93.65% | 26.73M | |
+34.97% | 51.07B | |
-7.74% | 38.78B | |
+35.88% | 38.61B | |
-10.62% | 27.32B | |
+11.66% | 26.35B | |
-17.89% | 19.46B | |
+40.95% | 13.58B | |
+29.75% | 12.46B | |
-3.15% | 11.75B |
- Stock Market
- Equities
- ULTI Stock
- News Ultimovacs ASA
- Ultimovacs ASA Reports Earnings Results for the First Quarter Ended March 31, 2024